Orion Oyj

Transaction in Own Shares • Jun 11, 2019

Disclosure 372715

Orion - Changes in company's own shares

Change in Orion Corporation's holding of treasury shares

ORION CORPORATION STOCK EXCHANGE RELEASE 11 JUNE 2019 at 11.45 EEST Change in Orion Corporation's holding of treasury shares A total of 238 Orion class B shares have been returned free of consideration to Orion Corporation by virtue of the terms of the Company's share-based incentive plan of the year 2016. After the transfer, Orion Corporation holds 765,399 of its own class B shares. Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Contact person: Olli Huotari, SVP, Corporate Functions tel. +358 010 426 3054 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland www.orion.fi Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. []